spinal
muscular
atrophi
sma
lead
genet
caus
infant
mortal
caus
reduc
level
function
surviv
motor
neuron
smn
protein
identifi
therapeut
agent
sma
establish
versatil
report
line
target
human
gene
screen
compound
librari
identifi
zfafmk
potent
candid
zfafmk
cystein
proteas
inhibitor
increas
function
smn
inhibit
proteasemedi
degrad
fulllength
exon
form
smn
studi
reveal
ctsb
ctsl
mediat
degrad
smn
protein
provid
novel
target
sma
notabl
zfafmk
mitig
mitochondriopathi
neuropathi
sma
patientderiv
motor
neuron
show
protect
effect
sma
anim
model
intracerebroventricular
inject
anoth
cystein
proteas
inhibitor
pass
bloodbrain
barrier
show
even
potent
therapeut
effect
subcutan
deliveri
sma
mice
taken
togeth
success
establish
human
report
futur
drug
discoveri
identifi
potenti
therapeut
valu
cystein
proteas
inhibitor
treat
sma
via
stabil
smn
protein
spinal
muscular
atrophi
sma
lead
genet
caus
infant
mortal
character
specif
degener
spinal
motor
neuron
caus
mutat
gene
pearn
et
al
pearn
burglen
et
al
lefebvr
et
al
human
uniqu
two
smn
gene
monani
et
al
rochett
et
al
gene
gener
fulllength
transcript
smnfl
function
surviv
motor
neuron
smn
protein
although
sequenc
gene
similar
differ
bp
gene
result
disrupt
splice
exon
smnfl
transcript
transcript
lack
exon
gener
monani
et
al
sma
patient
case
homozyg
delet
gene
even
patient
major
gene
product
nonstabl
degrad
quickli
thu
could
compens
loss
pearn
lefebvr
et
al
invers
correl
number
copi
diseas
sever
suggest
dosedepend
effect
function
smn
produc
gene
lefebvr
et
al
therefor
increas
function
smn
target
altern
gene
sma
patient
promis
therapeut
strategi
sma
wirth
et
al
zhou
et
al
singh
et
al
cherri
et
al
howel
et
al
dydewal
et
al
although
human
gene
report
gener
screen
candid
drug
studi
use
minigen
full
express
splice
regulatori
element
andreassi
et
al
zhang
et
al
lunn
et
al
mors
et
al
build
human
report
contain
element
human
gene
would
essenti
identifi
therapeut
agent
effect
rescu
motor
neuron
degener
sma
patient
smn
protein
ubiquit
express
protein
howev
reduc
level
protein
result
specif
degener
spinal
motor
neuron
shown
splice
smnfl
transcript
much
less
effici
spinal
motor
neuron
compar
type
neuron
ruggiu
et
al
moreov
stabil
smn
protein
also
affect
sma
shown
presenc
low
level
smnfl
oligomer
smnflsmnfl
significantli
reduc
reduc
level
smn
profound
effect
spinal
motor
neuron
lead
axon
defect
neuron
degener
addit
impair
axon
outgrowth
transport
recent
studi
report
dysfunct
mitochondria
mous
cell
smn
knockdown
suggest
smn
also
import
mitochondri
function
acsadi
et
al
impair
mitochondri
function
berger
et
al
ripolon
et
al
increas
oxid
stress
hayashi
et
al
also
report
sma
patient
success
establish
human
pluripot
stem
cellbas
model
sma
wang
et
al
xu
et
al
recapitul
diseasespecif
axon
phenotyp
select
motor
neuron
degener
interestingli
also
observ
mitochondri
defect
sma
spinal
motor
neuron
wang
et
al
xu
et
al
data
suggest
axon
defect
mitochondri
dysfunct
import
patholog
chang
sma
serv
uniqu
counter
assay
valid
candid
compound
take
advantag
recent
develop
gene
target
technolog
base
system
wang
et
al
mali
et
al
hou
et
al
niu
et
al
studi
seek
precis
specif
target
human
gene
build
uniqu
report
line
screen
drug
sma
upon
success
establish
report
cell
screen
small
compound
librari
compound
identifi
novel
small
molecul
increas
function
smn
compound
select
small
librari
significantli
increas
express
smn
protein
patient
cell
emphas
use
human
strategi
drug
screen
dissect
mechan
action
compound
examin
effect
compound
transcript
protein
stabil
ubiquitin
proteasom
cystein
proteas
pathway
final
determin
role
candid
compound
motor
neuron
degener
sma
examin
effect
compound
axon
mitochondri
defect
well
motor
neuron
loss
use
sma
induc
pluripot
stem
cell
ipsc
sma
mous
model
success
gener
versatil
human
report
line
cell
drug
screen
establish
versatil
report
target
human
gene
situ
use
homolog
recombin
hr
wang
et
al
mali
et
al
hou
et
al
niu
et
al
cell
grna
specif
target
gene
design
fig
verifi
target
effici
grna
cell
fig
use
grna
togeth
donor
plasmid
next
transfect
cell
calcium
phosphat
precipit
method
shown
fig
induc
doublestrand
break
dsb
promot
hrbase
dna
repair
presenc
recombin
donor
hr
gfp
specif
integr
gene
gener
report
fig
pleas
note
gfp
taa
stop
codon
specif
integr
replac
stop
codon
within
exon
premrna
splice
open
read
frame
includ
gfp
cassett
exon
exclud
contrast
taa
stop
codon
exon
make
open
read
frame
lack
gfp
exon
includ
compound
could
increas
smnfl
splice
effici
gfp
signal
decreas
howev
compound
potenti
transcript
figur
build
report
line
drug
screen
schemat
represent
grna
design
target
b
grna
target
effici
verifi
cell
overlap
peak
repres
nhej
repair
induc
dsb
c
schemat
strategi
report
line
establish
small
molecul
screen
induc
dsb
promot
hrbase
dna
repair
presenc
recombin
donor
gfp
specif
integr
exon
replac
stop
codon
exon
success
candid
small
molecul
either
brighten
transcript
enhanc
protein
stabil
darken
gfp
fluoresc
splice
pattern
switch
report
cell
count
hit
evalu
gfp
signal
increas
protein
unstabl
degrad
quickli
smn
protein
stabil
enhanc
compound
gfp
signal
also
increas
therefor
report
design
versatil
find
candid
drug
may
regul
transcript
splice
protein
stabil
next
transfect
cell
dissoci
singl
cell
cultur
clonal
gfpposit
clone
select
expand
fig
valid
integr
gfp
clone
show
correct
integr
indic
southern
blot
fig
genom
dna
pcr
fig
expect
express
fusion
protein
observ
report
line
fig
notabl
gfp
integr
specif
gene
reveal
dna
sequenc
fig
affect
normal
splice
pattern
human
gene
fig
togeth
data
reveal
success
establish
versatil
human
report
line
cell
drug
screen
use
report
identifi
compound
significantli
increas
smn
protein
level
test
feasibl
use
human
gene
report
drug
screen
use
report
posit
compound
regul
gene
transcript
activ
protirelin
kato
et
al
ohuchi
et
al
smn
protein
stabil
bortezomib
kwon
et
al
gene
splice
report
cell
treat
compound
vehicl
fluoresc
intens
examin
expect
protirelin
bortezomib
significantli
increas
gfp
intens
contrast
downregul
proport
splice
significantli
decreas
gfp
intens
report
cell
fig
assay
evalu
paramet
qualiti
assay
suggest
report
system
suitabl
drug
screen
zhang
et
al
examin
small
pool
librari
compound
report
cell
dissoci
plate
onto
plate
per
well
h
plate
compound
ad
fluoresc
intens
well
compar
compoundtr
vehicl
dmso
treat
group
result
identif
hit
brighten
gfp
fluoresc
report
line
fig
candid
compound
test
valid
repeat
show
great
repeat
fig
interestingli
four
candid
compound
belong
proteas
inhibitor
western
blot
analysi
confirm
sever
compound
could
e
sequenc
dna
sequenc
flank
gfp
cassett
confirm
gene
rather
gene
integr
f
gfp
integr
exon
show
normal
splice
pattern
splice
g
small
pool
librari
screen
identifi
hit
brighten
gfp
fluoresc
report
line
repres
pictur
compound
zfafmk
treatment
shown
scale
bar
h
quantif
data
show
hit
significantli
increas
gfp
intens
report
cell
line
data
present
mean
sem
n
p
p
compar
dmso
group
twotail
test
significantli
increas
protein
express
smn
patientderiv
fibroblast
among
compound
zpheala
fluoromethyl
keton
zfafmk
irrevers
inhibitor
cystein
proteas
van
noorden
et
al
effect
fig
next
examin
dosedepend
effect
zfafmk
smn
express
use
report
cell
line
treatment
differ
concentr
zfafmk
gfp
fluoresc
signal
brighter
cell
treat
higher
concentr
zfafmk
fig
express
fusion
protein
sampl
also
analyz
western
blot
confirm
dosedepend
effect
zfafmk
fig
c
interestingli
mrna
express
significantli
increas
zfafmktreat
group
compar
control
group
fig
suggest
zfafmk
inhibitor
cystein
proteas
van
noorden
et
al
may
affect
smn
stabil
evalu
compound
patient
sampl
examin
effect
zfafmk
mrna
protein
express
smn
fibroblast
cell
sma
patient
initi
diagnos
type
type
ii
sma
respect
similarli
describ
coriel
web
site
patient
fibroblast
cell
possess
gene
gene
use
taqman
qrtpcr
assay
gomezcuret
et
al
fig
protein
express
level
smn
fibroblast
cell
deriv
sma
patient
much
lower
normal
individu
wt
fig
treatment
differ
concentr
zfafmk
express
level
smn
protein
increas
zfafmk
dosedepend
manner
fig
statist
analysi
biolog
triplic
sampl
indic
zfafmk
significantli
increas
express
smn
protein
start
fig
similar
result
obtain
second
sma
patient
fibroblast
cell
fig
confirm
zfafmk
restor
smn
protein
level
patient
cell
notabl
zfafmk
could
increas
smn
protein
express
onefold
compar
highli
potent
agent
recent
report
similarli
seen
report
cell
zfafmk
sma
type
fibroblast
cell
vehicl
dmso
zfafmk
appli
follow
analysi
protein
e
f
mrna
g
express
cell
n
data
present
mean
sem
p
compar
dmsotreat
group
twotail
test
inhibit
cystein
proteas
sma
wang
et
al
http
vol
significantli
enhanc
mrna
express
smn
patient
fibroblast
cell
fig
togeth
data
reveal
effect
screen
system
identifi
small
molecul
zfafmk
novel
role
increas
protein
level
smn
role
zfafmk
smn
express
sma
patient
ipsc
ipscderiv
motor
neuron
valid
candid
compound
perform
secondari
analysi
use
sma
patientspecif
ipsc
success
gener
type
sma
patient
first
examin
effect
zfafmk
express
smn
protein
ipsc
fig
sma
ipsc
treat
zfafmk
differ
concentr
h
subsequ
harvest
western
blot
analysi
fig
protein
express
smn
significantli
increas
treatment
zfafmk
reveal
dosedepend
effect
fig
c
quantif
analys
reveal
protein
level
smn
significantli
increas
zfafmk
treat
sma
ipsc
compar
dmsotreat
control
fig
given
spinal
motor
neuron
specif
degener
sma
patient
examin
effect
zfafmk
express
smn
sma
patientderiv
spinal
motor
neuron
sma
ipsc
differenti
spinal
motor
neuron
use
modifi
monolay
differenti
system
presenc
retino
acid
caudal
purmorphamin
ventral
fig
similarli
previous
describ
ipsc
first
differenti
neuroepitheli
cell
ne
characterist
rosett
structur
fig
neural
precursor
differenti
spinal
motor
neuron
progenitor
subsequ
postmitot
spinal
motor
neuron
fig
zfafmk
appli
cultur
start
ne
stage
day
spinal
motor
neuron
cultur
express
function
smn
protein
dramat
increas
zfafmktreat
group
compar
dmsotreat
sma
spinal
motor
neuron
fig
cultur
sma
spinal
motor
neuron
degener
similarli
report
signific
increas
caspas
activ
reveal
increas
apoptosi
caus
defici
function
smn
longterm
cultur
interestingli
treatment
zfafmk
increas
caspas
activ
significantli
amelior
sma
motor
neuron
cultur
fig
togeth
data
suggest
candid
compound
zfafmk
effect
increas
function
smn
rescu
motor
neuron
degener
human
ipscbas
model
sma
western
blot
analysi
reveal
increas
express
smn
protein
zfafmk
treatment
motor
neuron
stage
e
activ
caspas
significantli
increas
motor
neuron
longterm
cultur
deriv
sma
ipsc
increas
significantli
inhibit
applic
zfafmk
mean
sem
n
p
compar
wt
group
p
compar
sma
dmso
group
twotail
test
dosedepend
effect
zfafmk
c
sma
ipsc
confirm
use
linear
regress
p
candid
compound
identifi
screen
zfafmk
inhibitor
cystein
proteas
van
noorden
et
al
examin
mechan
zfafmk
increas
smn
level
establish
doxycyclineinduc
cell
line
express
repres
differ
smn
isoform
smnfl
respect
fig
smnfl
protein
shown
potent
proteasom
inhibitor
stabil
smn
protein
inhibit
ubiquitinproteasom
pathway
chang
et
al
inde
led
dramat
increas
smnfl
protein
fig
dissect
role
zfafmk
perform
coimmunoprecipit
examin
ubiquitin
smn
protein
appli
zfafmk
data
show
zfafmk
unlik
caus
accumul
ubiquitin
smn
protein
fig
togeth
data
suggest
zfafmk
novel
role
stabil
smnfl
protein
inhibit
degrad
pathway
eg
proteasemedi
degrad
interest
smnfl
stabil
zfafmk
next
examin
stabil
smn
zfafmk
function
smn
protein
form
complex
gemini
often
local
cajal
bodi
nuclei
play
import
role
premrna
splice
gene
transcript
liu
dreyfuss
meister
et
al
use
gener
protein
gener
smnfl
protein
induc
line
compar
format
smn
gem
cajal
bodi
withdraw
doxycyclin
dmsoand
zfafmktreat
group
fig
expect
zfafmk
significantli
increas
amount
nuclear
smn
gem
cajal
bodi
doxycyclin
withdraw
line
fig
notabl
number
gem
also
significantli
increas
cell
treatment
zfafmk
fig
c
result
demonstr
smnfl
stabil
zfafmk
biolog
function
novel
role
cystein
proteasemedi
pathway
degrad
smn
protein
zfafmk
report
irrevers
cystein
proteas
inhibitor
van
noorden
et
al
prompt
us
investig
role
proteasemedi
degrad
stabil
smn
protein
notabl
two
famili
cystein
proteas
calpain
capn
cathepsin
ct
report
associ
initi
protein
degrad
neurodegener
yamashima
siklo
et
al
calpain
ca
ionactiv
nonlysosom
cystein
proteas
cathepsin
lysosom
proteas
enzym
yamashima
siklo
et
al
use
mrna
sequenc
first
examin
express
hcalpain
hcathepsin
forebrain
neuron
spinal
motor
neuron
deriv
ipsc
shown
fig
sever
capn
ctss
includ
ctsb
ctsl
highli
express
fragment
per
kilo
base
per
million
map
read
valu
human
ipscderiv
motor
neuron
impli
role
regul
degrad
smn
protein
human
motor
neuron
determin
effect
proteas
smn
express
screen
hcalpain
hcathepsin
rnai
librari
selleck
compani
establish
report
cell
line
found
fac
analysi
knockdown
ctsl
could
increas
intens
fig
c
similar
result
observ
two
differ
shrna
show
effect
knockdown
gene
express
fig
exclud
offtarget
effect
next
overexpress
proteas
found
ctsb
significantli
degrad
smnfl
protein
fig
e
furthermor
coimmunoprecipit
analys
show
physic
bind
cystein
proteas
smn
protein
fig
final
investig
effect
zfafmk
inhibit
proteasemedi
smn
protein
degrad
treat
cell
transfect
combin
proteas
ctsbctsl
zfafmk
h
combin
use
achiev
optim
inhibit
smn
protein
better
examin
effect
zfafmk
nonlysosom
lysosom
pathway
western
blot
analys
show
express
smn
protein
especi
significantli
reduc
transfect
proteas
reduct
mitig
least
partial
treatment
zfafmk
fig
togeth
data
demonstr
novel
role
nonlysosom
lysosom
cystein
proteas
ctsb
ctsl
mediat
smn
protein
degrad
zfafmk
partial
mitig
degrad
moreov
proteas
degrad
smn
protein
either
direct
bind
eg
calpain
mechan
includ
lysosomalmedi
pathway
eg
ctslctsb
provid
novel
target
therapeut
intervent
sma
effect
zfafmk
mitochondri
transport
defect
sma
sma
character
axon
synapt
defect
ever
et
al
kong
et
al
akten
et
al
dale
et
al
fallini
et
al
previou
studi
reveal
reduc
mitochondri
axon
transport
sma
ipscderiv
spinal
motor
neuron
dissect
protect
role
zfafmk
sma
examin
fast
axon
transport
mitochondria
essenti
local
synthesi
atp
area
axoplasm
distant
cell
bodi
day
mitochondri
axon
transport
examin
stain
mitotrack
red
cmxro
imag
everi
min
describ
previous
denton
et
al
fig
record
collect
imag
track
individu
mitochondria
use
metamorph
imag
analysi
softwar
quantifi
variou
transport
paramet
fig
c
sma
ipscderiv
spinal
motor
neuron
axon
observ
signific
reduct
percentag
motil
mitochondria
fig
frequenc
motil
event
fig
reveal
axon
transport
defect
sma
spinal
motor
neuron
examin
effect
zfafmk
axon
transport
defect
sma
small
molecul
ad
sma
ipscderiv
motor
neuron
cultur
start
neural
progenitor
stage
day
day
axon
transport
mitochondria
analyz
spinal
motor
neuron
cultur
compar
group
although
zfafmk
show
signific
effect
frequenc
motil
event
fig
percentag
motil
mitochondria
significantli
increas
sma
spinal
motor
neuron
cultur
treatment
zfafmk
fig
data
suggest
zfafmk
rescu
least
partial
impair
axon
transport
mitochondria
sma
ipscderiv
spinal
motor
neuron
role
zfafmk
mitochondri
dynam
motor
neuron
loss
sma
mitochondria
highli
dynam
constantli
undergo
fission
fusion
maintain
normal
shape
function
chan
otera
et
al
van
der
bliek
et
al
wagen
sma
patient
ipscderiv
spinal
motor
neuron
cultur
previou
studi
observ
abnorm
mitochondri
morpholog
neuron
indic
impair
mitochondri
dynam
determin
effect
small
molecul
mitochondri
dynam
compar
number
size
mitochondria
dmsoand
zfafmktreat
group
fig
spinal
motor
neuron
deriv
wt
control
sma
ipsc
stain
mitotrack
stain
motor
neuron
axon
imag
fig
number
morpholog
mitochondria
analyz
use
metamorph
softwar
describ
previous
sma
ipscderiv
motor
neuron
cultur
number
fig
area
fig
mitochondria
along
axon
significantli
decreas
compar
control
neuron
applic
zfafmk
significantli
inhibit
decreas
reveal
rescu
mitochondri
dynam
defect
spinal
motor
neuron
larg
project
neuron
high
energi
demand
specif
degener
sma
next
examin
zfafmk
mitig
motor
neuron
loss
longterm
cultur
although
decreas
smn
alter
initi
specif
motor
neuron
human
pluripot
stem
cell
wang
et
al
xu
et
al
neuron
degener
longterm
cultur
fig
shown
fig
proport
spinal
motor
neuron
significantli
decreas
sma
cultur
compar
control
group
fig
b
notabl
treatment
zfafmk
significantli
increas
proport
spinal
motor
neuron
level
compar
control
neuron
moreov
longterm
cultur
axon
degener
indic
axon
swell
breakdown
observ
sma
motor
neuron
cultur
also
mitig
treatment
zfafmk
fig
thu
result
reveal
zfafmk
effect
rescu
motor
neuron
loss
longterm
cultur
human
sma
model
suggest
zfafmk
compound
target
similar
pathway
serv
potent
therapeut
candid
sma
quantif
intens
show
signific
increas
knockdown
ctsl
data
present
mean
sem
n
p
compar
shrnacon
group
twotail
test
e
western
blot
quantif
data
show
overexpress
ctsb
significantli
degrad
smnfl
protein
mean
sem
n
p
p
compar
gfp
group
twotail
test
f
coimmunoprecipit
show
bind
smn
isoform
direct
bind
ctsbl
smn
isoform
protect
effect
cystein
proteas
inhibitor
sma
anim
model
evalu
role
zfafmk
vivo
environ
next
test
zfafmk
mous
model
mice
sever
diseas
phenotyp
die
quickli
birth
inject
mice
zfafmk
vehicl
dmso
later
cerebr
ventricl
start
postnat
day
daili
found
zfafmk
significantli
elev
smn
protein
level
spinal
cord
fig
increas
number
motor
neuron
lumbar
spinal
cord
fig
suggest
protect
properti
zfafmk
motor
neuron
loss
stabil
smn
protein
sma
mice
investig
effect
zfafmk
life
span
mice
mean
life
span
zfafmktreat
mice
wherea
control
mice
surviv
fig
reveal
trend
increas
life
span
treatment
zfafmk
signific
differ
bodi
weight
group
fig
appli
zfafmk
sma
neural
cultur
mitochondri
area
significantli
increas
data
present
mean
sem
wt
n
sma
dmso
n
smazfafmk
n
p
p
compar
wt
group
p
p
compar
smadmso
group
twotail
test
inhibit
cystein
proteas
sma
wang
et
al
http
vol
zfafmk
proven
cross
bloodbrain
barrier
bbb
thu
molecular
structur
modif
narrow
treatment
window
use
may
contribut
rel
limit
effect
life
span
sma
mice
next
improv
vivo
efficaci
replac
zfafmk
ethyl
ester
anoth
cystein
proteas
inhibitor
cross
bbb
cystein
proteas
inhibitor
report
protect
effect
brain
injuri
alzheim
diseas
kuwako
et
al
tsubokawa
et
al
tsubokawa
et
al
hook
et
al
prove
safe
use
human
first
examin
effect
vitro
found
similarli
zfafmk
also
trend
inhibit
degrad
mediat
overexpress
ctsb
ctsl
cell
fig
longterm
cultur
spinal
motor
neuron
deriv
sma
ipsc
treatment
significantli
increas
proport
motor
neuron
confirm
protect
effect
human
sma
motor
neuron
cultur
fig
f
data
suggest
also
potenti
treatment
agent
sma
test
mous
model
dmso
subcutan
inject
daili
start
spinal
smn
protein
fig
number
motor
neuron
fig
lumbar
spinal
cord
mice
significantli
increas
notabl
dmsotreat
mice
surviv
treatment
mean
life
span
mice
significantli
longer
increas
vehicletr
group
use
logrank
test
p
fig
also
increas
trend
bodi
weight
later
time
point
treatment
fig
taken
togeth
data
demonstr
cystein
proteas
inhibitor
zfafmk
significantli
inhibit
spinal
motor
neuron
loss
elong
life
span
mice
serv
potenti
therapeut
agent
sma
patient
sma
lead
genet
caus
death
among
infant
around
sma
patient
die
age
two
pearn
et
al
prior
kolb
kissel
sma
caus
reduc
level
function
smn
increas
function
smn
target
altern
gene
promis
therapeut
strategi
sma
wirth
et
al
zhou
et
al
singh
et
al
cherri
et
al
howel
et
al
challeng
approach
build
robust
effect
gene
report
contain
element
human
gene
studi
data
present
mean
sem
p
compar
wt
mice
p
p
p
compar
smadmso
group
twotail
test
success
establish
versatil
human
report
line
cell
use
hr
specif
target
gene
human
cell
situ
import
advantag
approach
report
regulatori
element
thu
effect
screen
therapeut
agent
shown
studi
use
report
drug
screen
small
pool
librari
effect
identifi
candid
small
molecul
significantli
increas
function
smn
lead
rescu
motor
neuron
degener
ipscbas
model
sma
mous
model
studi
also
demonstr
smn
protein
degrad
nonlysosom
lysosom
cystein
proteas
inhibitor
cystein
proteas
increas
function
smn
stabil
smnfl
protein
provid
novel
target
therapeut
approach
sma
degener
motor
neuron
sma
caus
decreas
level
smn
protein
level
function
smn
sma
patient
critic
diseas
sever
prognosi
type
die
age
two
wherea
type
ii
patient
copi
could
live
well
adulthood
lefebvr
et
al
consid
function
smn
level
sma
type
ii
patient
higher
type
increas
function
smn
may
dramat
effect
sma
patient
increas
function
smn
achiev
increas
transcript
switch
splice
stabil
smn
protein
examin
alter
gfp
fluoresc
intens
report
line
compound
increas
smn
abl
identifi
valid
use
patient
fibroblast
cell
motor
neuron
small
molecul
zfafmk
identifi
present
studi
increas
express
smn
protein
mrna
sma
patient
fibroblast
cell
ipsc
dosedepend
manner
suggest
compound
affect
protein
stabil
moreov
zfafmk
increas
express
function
smn
protein
sma
motor
neuron
compar
potent
modifi
addit
cystein
proteas
inhibitor
increas
function
smn
differ
mechan
compar
approv
sma
drug
hach
et
al
bishop
et
al
allow
futur
combin
therapi
consid
identif
novel
candid
small
librari
high
assay
data
suggest
effect
report
line
identifi
potenti
compound
increas
function
smn
gene
translat
smnfl
protein
degrad
ubiquitinproteasom
system
chang
et
al
burnett
et
al
unstabl
degrad
much
quicker
smnfl
halflif
around
half
compar
smnfl
similarli
cell
line
halflif
around
half
although
degrad
quickli
studi
use
sever
sma
mice
show
express
extend
life
span
mice
suggest
benefici
sma
model
le
et
al
one
possibl
mechan
underli
protect
effect
form
complex
smnfl
le
et
al
burnett
et
al
stabl
thu
enhanc
smnfl
protein
studi
demonstr
candid
compound
zfafmk
stabil
smnfl
protein
contribut
potent
effect
increas
function
smn
protein
importantli
smnfl
protein
abil
form
gem
cajal
bodi
nuclei
suggest
stabil
protein
function
furthermor
unlik
zfafmk
caus
accumul
ubiquitin
smn
protein
suggest
zfafmk
increas
smn
stabil
differ
mechan
ubiquitinationproteasom
pathway
zfafmk
irrevers
inhibitor
cystein
proteas
recent
studi
also
show
smn
may
cleav
calpain
calciumdepend
cystein
proteas
fuent
et
al
howev
known
whether
cystein
proteas
involv
degrad
smn
whether
inhibit
cystein
proteas
benefici
effect
sma
model
use
knockdown
overexpress
experi
identifi
critic
proteas
ctsb
ctsl
mediat
degrad
smn
protein
serv
novel
therapeut
target
sma
interestingli
observ
differenti
effect
knock
overexpress
cystein
proteas
exampl
overexpress
ctsl
effect
wherea
knockdown
ctsl
increas
smn
level
may
ctsl
import
initi
protein
degrad
await
investig
knockdown
experi
although
increas
shrna
target
individu
cystein
proteas
total
increas
smn
smnfl
inhibit
activ
multipl
proteas
would
higher
similarli
overexpress
combin
cystein
proteas
significantli
reduc
smn
protein
level
partial
restor
zfafmk
suggest
compound
stabil
smn
protein
inhibit
cystein
proteas
moreov
compound
increas
smn
stabil
combin
drug
target
mechan
eg
increas
smn
express
futur
combin
therapi
review
articl
studi
reveal
calpain
degrad
smn
protein
inhibit
calpain
benefici
sma
de
la
fuent
et
al
studi
coincid
find
importantli
data
demonstr
nonlysosom
eg
calpain
lysosom
cystein
proteas
eg
ctsl
ctsb
involv
degrad
smn
protein
lysosom
dysfunct
critic
patholog
chang
neurodegen
diseas
thu
lysosom
cystein
proteas
could
import
role
sma
detail
alter
nonlysosom
lysosom
cystein
proteas
well
role
pathogenesi
sma
investig
futur
sma
ipscderiv
spinal
motor
neuron
axon
mitochondri
defect
observ
follow
specif
degener
spinal
motor
neuron
recapitul
diseasespecif
phenotyp
test
efficaci
candid
compound
examin
effect
phenotyp
use
ipsc
anim
model
reduc
axon
mitochondri
transport
abnorm
mitochondri
morpholog
well
late
motor
neuron
degener
mitig
zfafmk
notabl
applic
zfafmk
abl
increas
life
span
mice
confirm
efficaci
zfafmk
vivo
zfafmk
could
pass
bbb
drug
administr
intracerebroventricularli
increas
time
window
drug
administr
test
proteas
inhibitor
pass
bbb
despit
potenti
pleiotrop
effect
inhibit
proteas
shown
safe
patient
clinic
trial
alzheim
diseas
traumat
brain
injuri
medtrack
data
reveal
significantli
increas
function
smn
mitig
motor
neuron
degener
sma
cell
model
vitro
neuron
activ
sma
motor
neuron
could
examin
use
electrophysiolog
analysi
futur
notabl
use
sma
mice
found
inject
significantli
elev
smn
protein
level
increas
number
spinal
motor
neuron
extend
life
span
sma
model
mice
confirm
efficaci
vivo
taken
togeth
studi
identifi
novel
role
zfafmk
rescu
motor
neuron
degener
sma
highlight
potenti
therapeut
approach
inhibit
proteasemedi
degener
pathway
treatment
sma
target
donor
vector
compris
homolog
sequenc
gfp
cassett
target
donor
grna
plasmid
transient
cotransfect
cell
invitrogen
use
calcium
phosphat
precipit
method
gfp
start
codon
exon
stop
codon
omit
hr
cell
select
enrich
gfp
fluoresc
clonal
cultur
singl
cell
plate
plate
posit
singl
clone
gfp
fluoresc
pick
valid
genom
dna
pcr
pcr
product
sequenc
confirm
correct
integr
accord
two
uniqu
sequenc
site
differ
gene
within
intron
primer
set
use
follow
gfp
genom
dna
pcr
forward
revers
intron
gfpr
determin
splice
pattern
total
rna
posit
clone
reversetranscrib
cdna
remov
rnase
h
invitrogen
min
cdna
amplifi
primer
gfpr
subsequ
ligat
tvector
takara
ta
clone
escherichia
coli
assess
pcr
analysi
differ
smn
isoform
could
separ
agaros
gel
drug
screen
small
librari
compound
report
cell
seed
plate
densiti
cell
per
well
h
small
librari
proteas
inhibitor
protein
kinas
inhibitor
epigenet
modifi
fdaapprov
drug
deliv
cell
cultur
compound
librari
ad
well
individu
final
concentr
treatment
plate
dmso
use
neg
control
final
concentr
selleck
bortezomib
final
concentr
ad
h
analysi
selleck
protirelin
final
concentr
selleck
final
concentr
medchemexpress
use
posit
control
h
chang
gfp
signal
intens
captur
fluoresc
microscopi
olympu
analyz
imagej
singl
cell
circl
constant
frame
imagej
fig
gfp
intens
frame
record
divid
area
select
region
get
averag
optic
densiti
frame
differ
field
well
calcul
get
averag
gfp
optic
densiti
cell
dead
cell
avoid
densiti
brighter
averag
densiti
entir
well
fig
likewis
averag
optic
densiti
background
cell
field
calcul
ultim
gfp
fluoresc
intens
cell
equal
averag
gfp
optic
densiti
minu
averag
background
optic
densiti
compound
could
brighten
darken
gfp
fluoresc
compar
dmsotreat
cell
regard
potenti
hit
factor
effect
measur
assess
qualiti
screen
assay
determin
fluoresc
intens
posit
sampl
use
imagej
describ
zhang
et
al
genom
dna
digest
ecori
bamhi
neb
would
gener
band
gfp
correctli
integr
digest
dna
electrophores
transfer
nylon
membran
millipor
linear
plasmid
bear
gfp
sequenc
use
posit
control
diglabel
gfp
probe
assembl
accord
manufactur
instruct
roch
membran
hybrid
hybrid
buffer
roch
wash
sd
room
temperatur
sd
hybrid
blot
block
probe
antidig
antibodi
roch
afterward
incub
fast
chemiluminesc
substrat
roch
alkalin
phosphatas
detect
gfp
probe
gener
follow
primer
ntermin
myctag
clone
plvxtightpuro
vector
clontech
ecori
bamhi
site
zhang
et
al
clone
plenti
vector
addgen
lentivir
vector
vsvg
plasmid
cotransfect
cell
use
calcium
phosphat
precipit
method
dish
fresh
medium
suppli
h
post
transfect
medium
contain
viral
particl
collect
filter
cell
incub
rtta
viral
supernat
make
induc
line
h
viral
infect
puromycin
deliv
select
drugresist
clone
cell
induc
doxycyclin
subsequ
cell
wash
thoroughli
dmem
medium
three
time
suppli
kosr
medium
degrad
smn
protein
experi
cell
first
induc
overexpress
myctag
smn
protein
doxycyclin
wash
abrog
induc
cell
treat
zfafmk
proteasom
inhibitor
dmso
h
cell
lyse
ripa
buffer
proteas
inhibitor
cocktail
sigmaaldrich
protein
concentr
determin
bca
kit
thermo
fisher
scientif
mycsmn
protein
subject
immunoprecipit
antimyc
antibodi
cell
signal
technolog
conjug
gagaros
roch
wash
three
time
ripa
buffer
subject
western
blot
analysi
human
ipsc
line
includ
wt
control
sma
ipsc
gener
normal
sma
fibroblast
cell
coriel
cell
repositori
use
episom
method
describ
ipsc
cultur
feeder
layer
irradi
mef
hesc
media
ngml
chang
daili
gener
spinal
motor
neuron
ipsc
ipsc
first
differenti
neuroepithelia
neural
medium
presenc
day
neuroepithelia
treat
retino
acid
purmorphamin
spinal
motor
neuron
induct
describ
spinal
motor
neuron
effici
gener
around
wk
differenti
express
variou
proteas
spinal
motor
neuron
forebrain
neuron
deriv
wt
ipsc
use
suspens
method
examin
mrnasequenc
use
illumina
hiseq
sequenc
data
deposit
arrayexpress
databas
access
number
cell
pellet
collect
lyse
lysi
buffer
proteas
inhibitor
cocktail
sigmaaldrich
particul
fraction
remov
centrifug
protein
separ
sdspage
subject
immunoblot
analysi
primari
antibodi
use
rabbit
antiactin
sigmaaldrich
rabbit
antigapdh
excel
bio
mous
antismn
abnova
mous
antimyc
cell
signal
technolog
rabbit
antiubiquitin
cell
signal
technolog
mous
antiflag
sigmaaldrich
rabbit
antiha
cell
signal
technolog
mous
antirhodopsin
huang
et
al
santa
cruz
horseradish
peroxidaseconjug
secondari
antibodi
detect
western
light
chemiluminesc
reagent
plu
pierc
quantifi
smn
protein
smn
band
intens
normal
actin
gapdh
compar
differ
group
use
imagej
softwar
rna
isol
cell
use
trizol
reagent
invitrogen
follow
manufactur
instruct
total
rna
use
synthes
cdna
use
iscript
cdna
synthesi
kit
biorad
accord
supplier
protocol
use
templat
quantit
realtim
polymeras
chain
reaction
qrtpcr
qrtpcr
reaction
perform
mixtur
contain
cdna
primer
sybr
green
pcr
master
mix
biorad
express
level
mrna
calcul
use
compar
ct
method
follow
primer
use
studi
proteas
rnai
screen
cell
transient
transfect
shrna
librari
selleck
compani
includ
hcalpain
famili
member
hcathepsin
b
hcathepsin
l
hcathepsin
random
sequenc
neg
control
knockdown
effici
confirm
normal
cell
fresh
medium
suppli
h
post
transfect
gfp
intens
decid
fac
analysi
cell
transfect
shrnacon
neg
control
serv
gfp
gate
target
sequenc
aggagattgacgagaactt
caattcctccaagacctat
tgcgatttatccagttgaa
ggcataatttaccctcaaa
aaagaccggagaaaccatt
gggagaagaacatgaagat
shrnacon
ttctccgaacgtgtcacgt
cell
transient
cotransfect
addgen
hatag
ctsb
addgen
ctsl
addgen
gfp
plasmid
neg
control
doxycyclineinduc
plasmid
fresh
medium
contain
doxycyclin
suppli
h
post
transfect
induc
express
mycsmn
isoform
cell
harvest
ripa
buffer
proteas
inhibitor
cocktail
sigmaaldrich
degrad
analysi
western
blot
zfafmk
ad
cell
cultur
h
studi
effect
smn
stabil
protein
interact
analys
smn
isoform
proteas
proteas
plasmid
plasmid
cotransfect
cell
coimmunoprecipit
spinal
motor
neuron
progenitor
plate
onto
polyornithineand
lamininco
dish
mattek
day
total
differenti
cell
stain
nm
mitotrack
red
cmxro
invitrogen
min
allow
visual
mitochondria
livecel
imag
perform
use
carl
zeiss
axiovert
microscop
equip
incub
chamber
axon
identifi
accord
morpholog
criteria
constant
thin
diamet
long
neurit
branch
direct
emerg
cell
bodi
imag
everi
min
yield
frame
quantif
perform
use
protocol
describ
previous
short
locat
mitochondrion
manual
select
use
track
point
function
metamorph
paramet
distanc
cell
bodi
veloc
record
mitochondria
chang
posit
least
three
consecut
frame
consid
motil
analyz
mitochondri
morpholog
straighten
imag
gener
measur
mitochondri
transport
use
measur
length
imag
axon
divid
number
mitochondria
within
region
analyz
mitochondri
densiti
analyz
mitochondri
area
total
mitochondri
area
measur
divid
number
mitochondria
within
region
coverslip
fix
paraformaldehyd
immunohistochemistri
perform
describ
previous
li
et
al
antigenantibodi
reaction
develop
appropri
fluorescenceconjug
secondari
antibodi
nuclei
visual
hoechst
stain
primari
antibodi
use
studi
includ
rabbit
antimyc
cell
signal
technolog
mous
anticoilin
santa
cruz
mous
antiislet
development
studi
hybridoma
bank
rabbit
r
rabbit
antitau
sigmaaldrich
goat
antichat
millipor
popul
motor
neuron
among
total
differenti
cell
hoechst
label
count
describ
previous
analyz
gem
number
blindli
select
field
imag
cell
per
group
cell
fix
h
doxycyclin
withdraw
number
mycsmn
gem
count
punctat
foci
colabel
coilin
cajal
bodi
marker
protein
divid
total
number
myc
cell
field
least
three
coverslip
three
four
field
coverslip
chosen
count
measur
activ
caspas
caspaseglo
assay
promega
carri
accord
manufactur
instruct
briefli
spinal
motor
neuron
cultur
dissoci
accutas
invitrogen
seed
plate
cell
per
well
reagent
incub
h
room
temperatur
luminesc
well
measur
use
wallac
multilabel
counter
mice
experi
perform
follow
protocol
approv
anim
care
use
committe
univers
illinoi
tongji
univers
heterozyg
mice
purchas
jackson
laboratori
carrier
mice
use
breed
offspr
mark
divid
two
group
either
compound
vehicl
dmso
treatment
mice
genotyp
death
wean
pcr
protocol
accord
jackson
laboratori
ng
zfafmk
dissolv
dmso
dmso
dilut
artifici
cerebrospin
fluid
hara
et
al
inject
later
cerebr
ventricl
mice
daili
start
follow
establish
protocol
hammond
et
al
neonat
pup
place
ice
hypotherm
anesthesia
till
cessat
movement
later
ventricl
identifi
distanc
sutur
eye
mm
ventral
skin
micro
syring
od
needl
use
inject
right
hemispher
pup
held
warm
till
recoveri
movement
place
back
dam
cage
mgkg
dissolv
dmso
dilut
corn
oil
vehicl
dmso
corn
oil
subcutan
inject
per
day
birth
mous
weigh
daili
measur
smn
protein
level
spinal
cord
compoundtr
dmsotreat
wt
sampl
collect
eppendorf
tube
weigh
homogen
ripa
buffer
proteas
inhibitor
cocktail
sigmaaldrich
assess
motor
neuron
patholog
mice
anesthet
avertin
perfus
pb
follow
paraformaldehyd
lumbar
spinal
cord
segment
three
five
fix
dehydr
transect
motor
neuron
immunostain
anticholin
acetyltransferas
chat
antibodi
section
mice
total
mice
group
evalu
statist
signific
mean
differ
among
differ
sampl
group
analyz
use
twotail
test
linear
regress
log
transform
dose
log
dose
use
examin
dosedepend
effect
zfafmk
analyz
life
span
sma
mice
kaplanmei
surviv
analysi
logrank
test
use
compar
differ
group
signific
level
defin
p
